title: RAD inhibition of sarcoma growth: implications for laryngeal transplantation.
abstract: OBJECTIVE
  Laryngeal transplantation has not been widely accepted because of concerns regarding accelerated tumor recurrences in the setting of nonspecific immunosuppression. Allotransplantation could potentially be offered to patients if immunosuppressive therapy could be demonstrated to exert tumor suppressive properties. Preliminary reports have demonstrated an antiproliferative effect of everolimus (RAD), a derivative of the immunosuppressant rapamycin.
  
  
  METHODS
  Forty-five 10-week-old inbred C57BL/6N (B6) mice were injected subcutaneously with 1 x 10(6) MCA205 sarcoma cells. On the third postinoculation day, the mice were divided into 4 treatment groups, undergoing daily gavage with RAD at 0, 0.2, 1.0, and 5.0 mg/kg per day for 10 consecutive days. Thereafter, treatment with RAD was discontinued and tumor size was measured every 2 days during treatment and biweekly until sacrifice on the 31st postinoculation day. Whole-blood trough levels (C(min)) were measured for each group.
  
  
  RESULTS
  Mean tumor diameter among the control animals and the mice treated with RAD 0.2 mg/kg per day demonstrated no significant difference (P > .07). Groups treated with RAD 1 and 5 mg/kg per day demonstrated significant growth inhibition between the 7th and the 23rd postinoculation days (P < .0001), with no significant differences being noted between these two groups (P > .09). Mean tumor suppressive whole-blood C(min)'s for the 1 and 5 mg/kg per day groups were 75.6 and 368.9 pg/microL, respectively.
  
  
  CONCLUSIONS
  RAD delivered at immunosuppressive doses of 1 and 5 mg/kg per day resulted in significant growth restriction of a fibrosarcoma in a murine model.
authors.affiliation: Head and Neck Institute, The Cleveland Clinic Foundation, Cleveland, OH, USA. knottp@ccf.org
authors.forename: Philip Daniel
authors.initials: PD
authors.lastname: Knott
authors.forename: Hidemasa
authors.initials: H
authors.lastname: Tamai
authors.forename: Marshall
authors.initials: M
authors.lastname: Strome
authors.forename: Fredrick
authors.initials: F
authors.lastname: Van Lente
authors.forename: Suyu
authors.initials: S
authors.lastname: Shu
mesh_terms: D000818:Animals; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D000068338:Everolimus; D005354:Fibrosarcoma / Q000188:drug therapy* / Q000473:pathology*; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D051379:Mice; D008810:Mice, Inbred C57BL; D020123:Sirolimus / Q000008:administration & dosage / Q000031:analogs & derivatives*; D012983:Soft Tissue Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D047368:Tumor Burden
chemical_list: D007166:Immunosuppressive Agents; D000068338:Everolimus; D020123:Sirolimus